Company: BIAF
Filing Date: 2025-06-27
Form Type: POS AM
Source: 0001641172-25-016927
Chunk: 72

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-06-27
Form: POS AM
Chunk 72
---
 March 2024 Common Warrants will only be entitled to receive from the Company or its successor entity, as of the date of consummation of such Fundamental Transaction, the same type or form of consideration (and in the same proportion), at the Black Scholes Value of the unexercised portion of the March 2024 Common Warrant that is being offered and paid to the holders of Common Stock in connection with the Fundamental Transaction, whether that consideration is in the form of cash, stock or any combination of cash and stock, or whether the holders of our Common Stock are given the choice to receive alternative forms of consideration in connection with the Fundamental Transaction.

Except as otherwise provided in the March 2024 Common Warrants or by virtue of such holder’s ownership of shares of our Common Stock, the holder of a March 2024 Common Warrants will not have the rights or privileges of a holder of our Common Stock, including any voting rights, until the holder exercises such warrant.

The terms of the March 2024 PA Warrants are similar to those of the March 2024 Common Warrants, including that they have an exercise price equal to $1.64 per share, except that they were immediately exercisable upon issuance and expire on the five-year anniversary of the date of issuance.

Support Agreements

Certain of our stockholders holding in excess of 21% of our outstanding shares of Common Stock have entered into a Support Agreement, pursuant to which such stockholders have agreed, at every meeting of the holders of our Common Stock that our stockholders are requested to vote upon a proposal to approve the exercise in full of the March 2024 Common Warrants and the issuance of the March 2024 Common Warrant Shares upon exercise of the March 2024 Common Warrants, to vote all of the shares of Common Stock that they own in favor the such proposal as well as any proposal to approve an adjournment of any such meeting of our stockholders for purposes of obtaining further votes in favor of the such proposal that are at any time or from time to time presented for consideration to our stockholders.

| 39 |

<div align='center'>THE AUGUST 2024 OFFERINGS</div>

Warrant Inducement

On August 2, 2024, we entered into the August Inducement Agreement with the Warrant Inducement Holders that had previously purchased March 2024 Common Warrants. Pursuant to the August Inducement Agreement, the Warrant Inducement Holders